Download Gene Section RPRM (reprimo, TP53 dependent G2 arrest mediator candidate)

Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Short Communication
RPRM (reprimo, TP53 dependent G2 arrest
mediator candidate)
Alejandro H Corvalan, Veronica A Torres
Laboratory of Molecular Pathology and Epidemiology, Department of Hemathology - Oncology, School of
Medicine - P Universidad Catolica de Chile, 391 Marcoleta St - Santiago 8330074 Chile (AHC, TorresVAT)
Published in Atlas Database: November 2011
Online updated version : http://AtlasGeneticsOncology.org/Genes/RPRMID42082ch2q23.html
DOI: 10.4267/2042/47283
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology
in the cytoplasm.
Identity
Function
Other names: FLJ90327, REPRIMO
HGNC (Hugo): RPRM
Location: 2q23.3
DNA/RNA
Reprimo is a candidate tumor suppresor gene involved
in the G2/M phase cell cycle arrest mediated by tumor
protein p53. Reprimo induces cell cycle arrest by
inhibiting the nuclear translocation of the Cdc2-Cyclin
B1 complex.
Description
Implicated in
Reprimo gene consists of 1 exon. The gene spans 1,47
kb of genomic DNA on the chromosome 2 in the minus
strand.
Various cancers
Note
The aberrant methylation of the promoter region of
Reprimo is a common event that may contribute to the
pathogenesis of some types of human cancer. Promoter
methylation of Reprimo was found in pancreatic cancer
(91%), gastric cancer (90%), gallbladder cancer (62%),
lymphomas (57%), colorectal cancer (56%) and
esophageal adenocarcinomas (40%). In breast cancer,
leukemias and lung cancer, promoter methylation of
Reprimo was found in less than 40% of tested cases.
Transcription
The mRNA is 1496 bp in length.
Protein
Description
The open reading frame encodes a 109 amino acid
protein with an estimated molecular weight of 11774
Da. Reprimo is a highly glycosylated protein which has
two sites in amino acids 7 and 18. The protein has a
potential transmembrane site covering amino acids 56
to 76.
Gastric cancer
Disease
Aberrant hypermethylation of Reprimo is frequently
found in primary gastric cancer as well as in pair
plasma samples. In plasma from asymptomatic
controls, Reprimo is infrequently methylated.
Therefore, plasmatic detection of Reprimo is a putative
biomarker for early detection of gastric cancer.
Expression
The expression of Reprimo is induced by tumor protein
p53 following X-ray irradiation.
Localisation
When Reprimo is ectopically expressed, it is localized
Atlas Genet Cytogenet Oncol Haematol. 2012; 16(3)
223
RPRM (reprimo, TP53 dependent G2 arrest mediator candidate)
Corvalan AH, TorresVA
The above histogram represents the percentage of positive cases for Reprimo and other genes (APC, SHP1, CDH-1, ER, SEMA3B and
3OST2) in 43 prospectively collected gastric cancer cases and 31 asymptomatic age- and gender-matched controls. Only Reprimo
shows a significant difference in plasma between gastric cancer and asymptomatic controls (Bernal et al., Clin Cancer Res.
2008;14:6264-9).
Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N,
Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW,
Wistuba II, Meltzer SJ, Gazdar AF. Aberrant methylation of
Reprimo in human malignancies. Int J Cancer. 2005 Jul
1;115(4):503-10
Pancreatic cancer
Disease
Aberrant hypermethylation of Reprimo is also common
in pancreatic cell lines (91%) and in pancreatic
adenocarcinomas (66%). Reprimo methylation is
correlated with poor prognosis in a large series of
resected pancreatic cancers. This fact raises the
possibility that aberrant methylation of Reprimo is an
epigenetic event that may have a mechanistic role in
pancreatic cancer.
Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, Paun
BC, Kan T, Cheng Y, Wang S, Yang J, Abraham JM, Meltzer
SJ. Reprimo methylation is a potential biomarker of Barrett'sAssociated esophageal neoplastic progression. Clin Cancer
Res. 2006 Nov 15;12(22):6637-42
Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue
CA, Yeo CJ, Goggins M. Aberrant methylation of Reprimo
correlates with genetic instability and predicts poor prognosis
in pancreatic ductal adenocarcinoma. Cancer. 2006 Jul
15;107(2):251-7
References
Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N,
Taniguchi T. Reprimo, a new candidate mediator of the p53mediated cell cycle arrest at the G2 phase. J Biol Chem. 2000
Jul 28;275(30):22627-30
Bernal C, Aguayo F, Villarroel C, Vargas M, Díaz I, Ossandon
FJ, Santibáñez E, Palma M, Aravena E, Barrientos C,
Corvalan AH. Reprimo as a potential biomarker for early
detection in gastric cancer. Clin Cancer Res. 2008 Oct
1;14(19):6264-9
Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ,
Cameron JL, Hruban RH, Goggins M. Discovery of novel
targets for aberrant methylation in pancreatic carcinoma using
high-throughput microarrays. Cancer Res. 2003 Jul
1;63(13):3735-42
This article should be referenced as such:
Corvalan AH, TorresVA. RPRM (reprimo, TP53 dependent G2
arrest mediator candidate). Atlas Genet Cytogenet Oncol
Haematol. 2012; 16(3):223-224.
Suzuki M, Shigematsu H, Takahashi T, Shivapurkar N,
Sathyanarayana UG, Iizasa T, Fujisawa T, Gazdar AF.
Aberrant methylation of Reprimo in lung cancer. Lung Cancer.
2005 Mar;47(3):309-14
Atlas Genet Cytogenet Oncol Haematol. 2012; 16(3)
224